GSTs contribute to drug resistance by detoxifying chemotherapy agents before they can exert their cytotoxic effects on cancer cells. This is particularly problematic in treatments involving alkylating agents, anthracyclines, and platinum-based drugs. The overexpression of GSTs can lead to the rapid elimination of these drugs from the cells, reducing their efficacy and necessitating higher doses or alternative treatments.
